TICKERNERD
Menu
VORVORHealthcare · Biotechnology

VOR Stock Forecast: Vor Biopharma, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$21
+1.23% on the day

The 9 Wall Street analysts covering Vor Biopharma, Inc. hold a median 12-month price target of $40 — +86.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.1B
Ticker Nerd rank
23 / 100
Median analyst target
$40
Analysts covering
9
Total return, dividends reinvested
1W
+10.1%
1M
+4.0%
YTD
+63.7%
1Y
−49.0%
From 52W high
−56.1%
From 52W low
+212.1%
$7
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vor Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Value
60
Issuance
48
Size
43
Revisions
43
Quality
21
Momentum
18
Growth
10
Volatility
8

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (8): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Vor Biopharma, Inc. — and when they’d sell — is the membership.

Wall Street

VOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26VORHigh $50Median $40Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $18Median $40High $50

The green dot is the last close — the median target sits +86.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.ReiteratesBuy$31
18 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026WedbushMaintainsNeutral$15 → $18
14 May 2026WedbushMaintainsNeutral—
15 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushMaintainsNeutral—
30 Mar 2026JefferiesInitiatesBuy—
19 Mar 2026Wells FargoInitiatesOverweight—
9 Jan 2026CitigroupInitiatesBuy—
19 Dec 2025JP MorganMaintainsOverweight—
17 Dec 2025TD CowenInitiatesBuy—
9 Dec 2025JP MorganInitiatesOverweight—
25 Nov 2025WedbushAssumesNeutral$9.00
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
29 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025BairdUpgradeOutperform—
14 Aug 2025HC Wainwright & Co.ReiteratesBuy—
30 June 2025HC Wainwright & Co.UpgradeBuy—
27 June 2025BairdMaintainsNeutral—
26 June 2025WedbushReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

VOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Vor Biopharma, Inc. (VOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
−6.0×

Cheaper than 97% of US stocks

EV / EBITDA
−1.9×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
423.6%

Higher than 99% of US stocks

Return on assets
−69.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VORVor Biopharma, Inc.$1.1B
23
ORICOric Pharmaceuticals, Inc.$1.1B
49
LBRXLB Pharmaceuticals, Inc.$1.1B
9
IMTXImmatics NV$1.2B
54
JBIOJade Biosciences, Inc.$1.2B
22
CRVSCorvus Pharmaceuticals, Inc.$1.1B
62
ARDXArdelyx, Inc.$1.2B
51
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VOR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest VOR news & analysis

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Aug 2026neutral

On August 1, 2026, Vor Bio's Compensation Committee granted stock options to purchase 32,550 shares and RSUs for 6,900 shares of common stock to five newly hired employees. The grants were made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and the company's 2023 Inducement Plan.

Why it matters — VOR watchers would note this as a routine disclosure of equity-based compensation tied to new hires, reflecting the company's use of inducement awards to attract talent.

FAQ

Frequently asked questions about VOR stock

What is the VOR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Vor Biopharma, Inc. have a median 12-month price target of $40, with estimates ranging from $18 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VOR stock a buy right now?

Of the 9 analysts covering Vor Biopharma, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vor Biopharma, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VOR?

As at 1 Aug 2026, Vor Biopharma, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will VOR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +86.8% from the last close, and Ticker Nerd's factor model ranks Vor Biopharma, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VOR stock forecast for 2030?

No analyst covering Vor Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $50 over the next 12 months.

How has VOR stock performed over the past year?

Vor Biopharma, Inc. returned -49.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vor Biopharma, Inc. do?

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through innovative therapies.

What is the latest news on VOR?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". On August 1, 2026, Vor Bio's Compensation Committee granted stock options to purchase 32,550 shares and RSUs for 6,900 shares of common stock to five newly hired employees. The grants were made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and the company's 2023 Inducement Plan.

Company

About Vor Biopharma, Inc.

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through innovative therapies. Its lead program, telitacicept, is a novel dual BAFF/APRIL inhibitor designed to target the root causes of autoimmunity by silencing signals that drive harmful B-cell maturation, proliferation, and survival, thereby reducing autoantibody production and downstream tissue damage. This fusion protein aims to serve as a foundational therapy for serious B-cell-mediated conditions such as systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis. Telitacicept is approved in China for these indications and supports ongoing efforts in Phase 3 clinical development for additional autoantibody-driven diseases worldwide. Vor Biopharma Inc. operates within the health technology sector, emphasizing targeted biologics to restore immune system balance and address unmet needs in large patient populations across autoimmune disorders. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company combines expertise in biologics development to advance its pipeline in this critical therapeutic area.

CEO Dr. Jean-Paul Kress M.D. · 76 employees · United States · https://www.vorbio.com